RPRX Dec 2024 17.500 call
- GuruFocus.com
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight
Decoding the Financials and Future Prospects in Royalty Pharma's Latest 10-Q Filing
- GlobeNewswire
Royalty Pharma Reports First Quarter 2024 Results
Royalty Receipts growth of 14% driving Portfolio Receipts of $717 millionNet cash provided by operating activities of $665 millionFull year 2024 guidance confirmed: Portfolio Receipts expected to be $2,600 to $2,700 millionCommitment to grow dividend by mid-single digit percentage annually NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2024 and confirmed full year 2024 guidance for Portfolio Receipts. “We con
- GlobeNewswire
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseasesExpands Royalty Pharma’s development-stage portfolio to 15 therapies with the combined potential to generate significantly greater than $1 billion in annual peak royalties Royalty Pharma to highlight the strength of its development-stage pipeline on its first quarter of 2024 financial results call today at 8:00 a.m. NEW YORK, May 09, 2024 (GLOBE NEWSWIR
